Grigor, Emma J MFergusson, Dean AHaggar, FatimaKekre, NatashaAtkins, HaroldShorr, RisaHolt, Robert AHutton, BrianRamsay, TimSeftel, MatthewJonker, DerekDaugaard, MadsThavorn, KednapaPresseau, JustinLalu, Manoj M2019-04-122019-04-1220172044-6055https://doi.org/10.20381/ruor-23312http://hdl.handle.net/10393/39063Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CAR-T) cells redirects a patient's immune cells against the tumour antigen. CAR-T cell therapy has demonstrated promise in treating patients with several haematological malignancies, including acute B-cell lymphoblastic leukaemia and B-cell lymphomas. CAR-T cell therapy for patients with other solid tumours is also being tested. Safety is an important consideration in CAR-T cell therapy given the potential for serious adverse events, including death. Previous reviews on CAR-T cell therapy have been limited in scope and methodology. Herein, we present a protocol for a systematic review to identify CAR-T cell interventional studies and examine the safety and efficacy of this therapy in patients with haematology malignancies and solid tumours.encar-tchimeric antigen receptorleukaemialymphomamalignancymyelomaHematologic NeoplasmsHumansImmunotherapyLymphoma, B-CellNeoplasmsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSystematic Reviews as TopicAntigens, NeoplasmReceptors, Antigen, T-CellT-LymphocytesArticle10.1136/bmjopen-2017-019321